MedTrace Logo

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

NCT04003246 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-03-21

Study results available
· View outcomes & findings →

Summary

Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)

Conditions

  • Non Small Cell Lung Cancer
  • Lung Cancer Stage III

Interventions

RADIATION

Thoracic RT and Durvalumab

1500mg every 4 weeks \[Q4W\] intravenous \[IV\], first dose within 3 days of RT initiation

DRUG

Consolidative Durvalumab

1500mg every 4 weeks \[Q4W\] intravenous \[IV\] up to one year

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Yuanyuan Zhang, MD · UT Southwestern Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-03
Primary Completion
2022-06-15
Completion
2024-11-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04003246 on ClinicalTrials.gov